US 12,139,523 B2
Anti-LMP2 TCR-T cell therapy for the treatment of EBV-associated cancers
Xiao-Fan Wang, Durham, NC (US); Peter Alexander, Durham, NC (US); Qi-Jing Li, Durham, NC (US); and Guoping Wang, Durham, NC (US)
Assigned to Duke University, Durham, NC (US)
Appl. No. 17/276,553
Filed by DUKE UNIVERSITY, Durham, NC (US)
PCT Filed Nov. 26, 2019, PCT No. PCT/US2019/063310
§ 371(c)(1), (2) Date Mar. 16, 2021,
PCT Pub. No. WO2020/112815, PCT Pub. Date Jun. 4, 2020.
Claims priority of provisional application 62/771,653, filed on Nov. 27, 2018.
Prior Publication US 2022/0056101 A1, Feb. 24, 2022
Int. Cl. C07K 14/725 (2006.01); A61K 35/17 (2015.01); A61P 35/00 (2006.01); C07K 16/08 (2006.01)
CPC C07K 14/7051 (2013.01) [A61K 35/17 (2013.01); A61P 35/00 (2018.01); C07K 16/085 (2013.01)] 19 Claims
 
1. A population of T-cells comprising an engineered T-cell receptor (TCR), wherein the engineered TCR activates T-cells in response to a Latent membrane protein 2 (LMP2) antigen; and wherein the engineered TCR comprises a variable alpha chain comprising the sequence as set forth in SEQ ID NO:4, and a variable beta chain comprising the amino acid sequence as set forth in SEQ ID NO:6; or a variable alpha chain comprising the sequence set forth in SEQ ID NO:10 and a variable beta chain comprising the sequence set forth in SEQ ID NO: 12.